Dynamic Nonlinear X-waves for Femtosecond Pulse Propagation in Water

Recent experiments on femtosecond pulses in water displayed long distance propagation analogous to that reported in air. We verify this phenomena numerically and show that the propagation is dynamic as opposed to self-guided. Furthermore, we demonstrate that the propagation can be interpreted as due to dynamic nonlinear X-waves whose robustness and role in long distance propagation is shown to follow from the interplay between nonlinearity and chromatic dispersion.Comment: 4 page

Nanomicellar Lenalidomide-Fenretinide Combination Suppresses Tumor Growth in an MYCN Amplified Neuroblastoma Tumor

Purpose: In a previous study, we demonstrated that the combination of fenretinide with lenalidomide, administered by a novel nanomicellar formulation (FLM), provided a strong antitumor effect in a neuroblastoma TrkB-expressing tumor. In this study, we tested the nanomicellar combination in an MYCN amplified neuroblastoma xenograft to assess its efficacy in different tumor genotypes and evaluate the interactions of the nanomicelles with the tumor cells. Experimental Design: FLM was administered to mice bearing human NLF xenografts to evaluate its efficacy in comparison with the nanomicelles containing fenretinide alone (FM). Confocal laser-scanning fluorescence microscopy images of the NLF cells treated with FLM and FM allowed us to estimate the nanomicelle ability to transport the encapsulated drugs inside the tumor cells. Flow cytometric analysis of the cells from treated tumors was performed to assess the effect of treatment on GD2 expression and NK cell infiltration. Results: FLM and FM decreased the growth of NLF xenografts at comparable extents during the treatment period. Afterwards, FLM induced a progressive tumor regression without regrowth, while FM treatment was followed by regrowth within 15-20 days after the end of treatment. Both FLM and FM were able to penetrate the tumor cells transporting the encapsulated drugs. FLM transported higher amount of fenretinide inside the cells. Also, FLM treatment strongly increased GD2 expression in treated tumors and slightly decreased the NK infiltration compared to FM. Conclusion: FLM treatment induced a superior antitumor response than FM in NLF xenografts, presumably due to the combined effects of fenretinide cytotoxicity and lenalidomide antiangiogenic activity. The ability of FLM to penetrate tumor cells, transporting the encapsulated drugs, substantially improved the therapeutic efficiency of this system. Moreover, the enhancement of GD2 expression in FLM treated tumors offers the possibility to further increase the antitumor effect by the use of anti-GD2 CAR-T cells and anti-GD2 antibodies in combination with FLM in multimodal therapies

Highly charged ions in Penning traps, a new tool for resolving low lying isomeric states

The use of highly charged ions increases the precision and resolving power, in particular for short-lived species produced at on-line radio-isotope beam facilities, achievable with Penning trap mass spectrometers. This increase in resolving power provides a new and unique access to resolving low-lying long-lived ($T_{1/2} > 50$ ms) nuclear isomers. Recently, the $111.19(22)$ keV (determined from $\gamma$-ray spectroscopy) isomeric state in $^{78}$Rb has been resolved from the ground state, in a charge state of $q=8+$ with the TITAN Penning trap at the TRIUMF-ISAC facility. The excitation energy of the isomer was measured to be $108.7(6.4)$ keV above the ground state. The extracted masses for both the ground and isomeric states, and their difference, agree with the AME2003 and Nuclear Data Sheet values. This proof of principle measurement demonstrates the feasibility of using Penning trap mass spectrometers coupled to charge breeders to study nuclear isomers and opens a new route for isomer searches.Comment: 8 pages, 6 figure

First direct mass-measurement of the two-neutron halo nucleus 6He and improved mass for the four-neutron halo 8He

The first direct mass-measurement of $^{6}$He has been performed with the TITAN Penning trap mass spectrometer at the ISAC facility. In addition, the mass of $^{8}$He was determined with improved precision over our previous measurement. The obtained masses are $m$($^{6}$He) = 6.018 885 883(57) u and $m$($^{8}$He) = 8.033 934 44(11) u. The $^{6}$He value shows a deviation from the literature of 4$\sigma$. With these new mass values and the previously measured atomic isotope shifts we obtain charge radii of 2.060(8) fm and 1.959(16) fm for $^{6}$He and $^{8}$He respectively. We present a detailed comparison to nuclear theory for $^6$He, including new hyperspherical harmonics results. A correlation plot of the point-proton radius with the two-neutron separation energy demonstrates clearly the importance of three-nucleon forces.Comment: 4 pages, 2 figure

Expanding RIB Capabilities at the Cyclotron Institute: \textsuperscript{3}He-LIG production with an Isobar Separator LSTAR

A new \textsuperscript{3}He-driven IGISOL production station and mass separator have been designed to produce neutron-deficient low-mass isotopes at the Cyclotron Institute for the TAMUTRAP facility. The LSTAR design has a mass resolution $M/\Delta M\geq 3, 000$ to reject contaminants with $\gt95\%$ efficiency.Comment: Proceeding for EMIS 202

First Penning-trap mass measurement in the millisecond half-life range: the exotic halo nucleus 11Li

In this letter, we report a new mass for $^{11}$Li using the trapping experiment TITAN at TRIUMF's ISAC facility. This is by far the shortest-lived nuclide, $t_{1/2} = 8.8 \rm{ms}$, for which a mass measurement has ever been performed with a Penning trap. Combined with our mass measurements of $^{8,9}$Li we derive a new two-neutron separation energy of 369.15(65) keV: a factor of seven more precise than the best previous value. This new value is a critical ingredient for the determination of the halo charge radius from isotope-shift measurements. We also report results from state-of-the-art atomic-physics calculations using the new mass and extract a new charge radius for $^{11}$Li. This result is a remarkable confluence of nuclear and atomic physics.Comment: Formatted for submission to PR

A novel nanomicellar combination of fenretinide and lenalidomide shows marked antitumor activity in a neuroblastoma xenograft model

Purpose: Currently >50% of high-risk neuroblastoma (NB) patients, despite intensive therapy and initial partial or complete response, develop recurrent NB due to the persistence of minimal residual disease (MRD) that is resistant to conventional antitumor drugs. Indeed, their low therapeutic index prevents drug-dose escalation and protracted administration schedules, as would be required for MRD treatment. Thus, more effective and less toxic therapies are urgently needed for the management of MRD. To address this aim, we evaluated a new combination of fenretinide and lenalidomide, both endowed with antitumor activity and low-toxicity profiles. New nanomicelles were prepared as carriers for this combination to maximize bioavailability and accumulation at the tumor site because of the enhanced permeability and retention (EPR) effect. Experimental design: New nanomicelles containing the fenretinide\u2013lenalidomide combination (FLnMs) were prepared by a one-step method, providing high drug encapsulation and micelle dimensions suitable for tumor accumulation. Their administration to mice bearing human NB xenografts allowed us to evaluate their efficacy in comparison with the nanomicelles containing fenretinide alone (FnMs). Results: Treatment by FLnMs significantly decreased the tumor growth of NB xenografts. FLnMs were more active than FnMs despite comparable fenretinide concentrations in tumors, and lenalidomide alone did not show cytotoxic activity in vitro against NB cells. The tumor mass at the end of treatment with FLnMs was predominantly necrotic, with a decreased Ki-67 proliferation index. Conclusion: FLnMs provided superior antitumor efficacy in NB xenografts compared to FnMs. The enhanced efficacy of the combination was likely due to the antiangiogenic effect of lenalidomide added to the cytotoxic effect of fenretinide. This new nanomicellar combination is characterized by a low-toxicity profile and offers a novel therapeutic option for the treatment of high-risk tumors where the persistence of MRD requires repeated administrations of therapeutic agents over long periods of time to avoid recurrent disease